A prospective observational cohort study at a national center during the first 30 pandemic months was conducted, focusing on an immunomodulatory treatment effect (dexamethasone, IL-6R/JAK-inhibition) on secondary bacterial and fungal infections among 379 critically ill COVID-19 adult patients. Here, IL6R is linked to COVID-19.